(Q39454135)

12 September 2017

title

Doxazosin in men with lower urinary tract symptoms: urodynamic evaluation at 15 months (English)

1 reference

12 September 2017

Gerber GS

1

1 reference

12 September 2017

Contreras BA

2

1 reference

12 September 2017

Zagaja GP

3

1 reference

12 September 2017

Kim JH

4

1 reference

12 September 2017

Steinberg GD

5

1 reference

12 September 2017

Rukstalis DB

6

1 reference

12 September 2017

language of work or name

English

0 references

publication date

1 August 1997

1 reference

12 September 2017

1 reference

12 September 2017

volume

50

1 reference

12 September 2017

issue

2

1 reference

12 September 2017

page(s)

229-233

1 reference

Effect of terazosin on urine storage and voiding in the aging male with prostatism

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900189-1

7 January 2021

An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900189-1

7 January 2021

A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900189-1

7 January 2021

A 12-week placebo-controlled double-blind study of prazosin in the treatment of prostatic obstruction due to benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900189-1

7 January 2021

Effects of Prazosin in Patients with Benign Prostatic Obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900189-1

7 January 2021

Practice trends in the diagnosis and management of benign prostatic hyperplasia in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900189-1

7 January 2021

The Abrams-Griffiths nomogram

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900189-1

7 January 2021

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900189-1

7 January 2021

Comparison of aua symptom index in unselected males and females between fifty-five and seventy-nine years of age

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900189-1

7 January 2021

Variability of Clinical and Pressure-Flow Study Variables After 6 Months of Watchful Waiting in Patients with Lower Urinary Tract Symptoms and Benign Prostatic Enlargement

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900189-1

7 January 2021

The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900189-1

7 January 2021

Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900189-1

7 January 2021

10.1016/S0090-4295(97)00189-1

Identifiers

DOI

1 reference

12 September 2017

1 reference